73.9 F
New York
Thursday, August 11, 2022

Date:

Share:

Peripheral NOP agonist addressing chronic peripheral neuropathic pain enters clinical development

Related Articles

VMRD Begins Manufacturing Key Reagent for Detection of CWD by RT-QuIC

Pullman, WA, August 09, 2022 --(PR.com)-- Veterinary Medical Research & Development (VMRD), Pullman, WA, has partnered with CWD Evolution, Fort Collins, CO, to provide state-of-the-art...

Aachen, Germany, 16 December 2020 – Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of chronic peripheral neuropathic pain.

The Phase I trial will include 76 healthy participants. The trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound following single and multiple-ascending doses. The results of the study are expected to be available in 2021.

“Pain remains a high unmet medical need that we strive to address with innovative medicines. Progressing our peripheral NOP agonist into clinical development is a major success in our efforts to build an industry-leading pipeline of investigational medicines,” says Jan Adams, M.D., Chief…

Read more…

Popular Articles